[O8] Oral Session 8　Lung Cancer / Thoracic Cancer 2（Immune Checkpoint Inhibitors）
【E】

[O8-5] First-line nivolumab (N) + ipilimumab (I) in unresectable malignant pleural mesothelioma (MPM): CheckMate 743 3-y data

^○Nobukazu Fujimoto¹, Solange Peters², Arnaud Scherpereel³, Robin Cornelissen⁴, Youssef Oulkhouir⁵, Laurent Greillier⁶, Muhammet Ali Kaplan⁷, Toby Talbot⁸, Isabelle Monnet⁹, Sandrine Hiret¹⁰, Paul Baas¹¹, Anna K. Nowak¹², Anne S. Tsao¹³, Aaron S. Mansfield¹⁴, Sanjay Popat¹⁵, Xiaoqing Zhang¹⁶, Nan Hu¹⁶, David Balli¹⁶, Jenine Sanzari¹⁶, Gerard Zalcman¹⁷ (1.Department of Medical Oncology, Okayama Rosai Hospital, 2.Lausanne University Hospital, Lausanne, Switzerland, 3.University of Lille, CHU Lille, INSERM, OncoThAI, Lille, France, 4.Erasmus MC Cancer Institute, Rotterdam, Netherlands, 5.Hôpital Côte de Nacre CHU Caen, Caen, France, 6.Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France, 7.Dicle University, Diyarbakir, Turkey, 8.Royal Cornwall Hospitals NHS Trust, Truro, UK, 9.Centre Hospitalier Intercommunal de Creteil, Créteil, France, 10.Institut de Cancérologie de l'Ouest, Saint-Herblain Cedex, France, 11.Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, Netherlands, 12.University of Western Australia and Sir Charles Gairdner Hospital, Perth, Australia, 13.MD Anderson Cancer Center, Houston, TX, USA, 14.Mayo Clinic, Rochester, MN, USA, 15.Royal Marsden Hospital and Institute of Cancer Research, London, UK, 16.Bristol Myers Squibb, Princeton, NJ, USA, 17.Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, France)